Regenerative science company StimLabs has reported findings from a multi-centre trial of its fenestrated dehydrated complete human placental membrane (dCHPM) allograft, Relese, when used alongside standard of care for wounds that are hard to heal.
The observational analysis reviewed both clinical findings and safety in day-to-day care settings.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Data from the per-protocol population indicated that 78% of wounds closed, with the median time to closure recorded at 49 days.
The mean reduction in wound area was found to be 86%.
Relese was also linked to considerable wound closure rates and a favourable safety profile across varied treatment environments.
The research highlights the possible role of dCHPM allografts within comprehensive wound management approaches for wounds resistant to usual therapies.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataStimLabs chief commercial officer and executive vice-president Tom Dion said: 鈥淭hese data support Relese鈥檚 role as an adjunctive therapy in the treatment of chronic wounds, including diabetic foot and neuropathic ulcers.
鈥淥ur findings validate the importance of real-world data and our commitment to delivering evidence-based solutions that have a positive impact on patients鈥� lives.鈥�
Relese operates as a selective barrier, providing protection for the wound while permitting fluid drainage.
The product retains all three amnion, intermediate and chorion placental membrane layers, along with essential structural elements, via the patented Clearify technology.
In 2024, StimLabs’ wound care device, Corplex P, received 510(k) clearance from the US Food and Drug Administration (FDA).
Corplex P is said to be the first graft developed from human umbilical cord extracellular matrix (ECM) to address acute and chronic wounds, including diabetic ulcers, trauma injuries, and surgical wounds.
In November 2024, Geistlich Pharma entered an exclusive national distribution partnership agreement with StimLabs, focusing on the commercialisation of the former鈥檚 Advanced Wound Matrix, Derma-Gide.
